The stock has underperformed its sector peers, with a day change of -1.47% and a three-day cumulative return of -4.29%. Currently, Shree Ganesh Biotech India is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a sustained downward trend in its price momentum.
In contrast, the broader market has shown resilience. The Sensex opened higher at 85,470.92 points, gaining 284.45 points or 0.33%, and is trading close to its 52-week high of 85,290.06. The index remains supported by mega-cap stocks and is positioned above its 50-day and 200-day moving averages, signalling a generally bullish market environment that Shree Ganesh Biotech India has not mirrored.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Over the past year, Shree Ganesh Biotech India’s stock price has declined by 37.38%, while the Sensex has recorded a positive return of 9.94%. This divergence highlights the challenges faced by the company relative to the broader market. The stock’s 52-week high was Rs.1.19, indicating that the current price represents a significant contraction in market value.
Financially, the company’s recent results have shown contraction in key metrics. Net sales for the nine-month period stood at Rs.5.16 crores, reflecting a reduction of 44.64% compared to the previous period. The net loss after tax for the same period was Rs.0.61 crores, also showing a decline of 44.64%. These figures point to a contraction in revenue and profitability over the recent reporting period.
Additional financial ratios underline the company’s current position. The average EBIT to interest ratio is 0.91, suggesting limited capacity to cover interest expenses from operating earnings. Return on equity has averaged 2.62%, indicating modest profitability relative to shareholders’ funds. The debtors turnover ratio for the half-year period is recorded at 0.00 times, which may reflect challenges in receivables management or collection efficiency.
Profitability has also been under pressure, with EBITDA figures turning negative, a factor that contributes to the stock’s classification as risky when compared to its historical valuation levels. Over the last year, profits have declined by 86.6%, further emphasising the financial strain on the company.
Holding Shree Ganesh Biotech India from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Shareholding patterns reveal that the majority of shares are held by non-institutional investors, which may influence liquidity and trading dynamics. The company’s long-term fundamental strength is considered weak, reflecting the financial metrics and recent performance trends.
In summary, Shree Ganesh Biotech India’s stock has reached a new low point at Rs.0.65, reflecting a year marked by declining revenues, losses, and subdued profitability ratios. While the broader market and sector indices have shown strength, the company’s share price and financial indicators illustrate the challenges it currently faces within the Pharmaceuticals & Biotechnology industry.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
